{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-WM3ZV7M3/444e3dc8-14fd-4937-87e8-1195f92ad504/PDF","dcterms:extent":"681 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-WM3ZV7M3/93803ecf-4a55-4862-b136-ea4cf2da70d8/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-WM3ZV7M3","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2024","dc:creator":"Lunder, Mojca","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:75"},{"@xml:lang":"sl","#text":"str. 130-136"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:196225795","URN:URN:NBN:SI:doc-WM3ZV7M3"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"aducanumab"},{"@xml:lang":"sl","#text":"adukanumab"},{"@xml:lang":"en","#text":"Alzheimer’s disease"},{"@xml:lang":"sl","#text":"Alzheimerjeva bolezen"},{"@xml:lang":"en","#text":"biological drugs"},{"@xml:lang":"sl","#text":"Biološka zdravila"},{"@xml:lang":"en","#text":"lecanemab"},{"@xml:lang":"sl","#text":"lekanemab"},{"@xml:lang":"en","#text":"monoclonal antibodies"},{"@xml:lang":"sl","#text":"monoklonska protitelesa"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Biološke učinkovine pri Alzheimerjevi bolezni| Biopharmaceuticals for Alzheimer’s disease|"},"dc:description":[{"@xml:lang":"sl","#text":"According to the beta amyloid hypothesis the main cause of Alzheimer’s disease is accumulation of amyloid plaques in the brain tissue and subsequent intracellular deposits of tau protein. In the development of biopharmaceuticals for treatment of Alzheimer’s disease, researchers focused mainly on targets related to the formation of amyloid plaques, neurofibrillary tangles and on targets affecting the activity of glia cells and the inflammatory response in the central nervous system. Monoclonal antibodies directed against components of the amyloid pathway have achieved the most success thus far. Aducanumab and lekanemab have recently obtained marketing authorization in the USA via the expedited clearance pathway based on the achievement of a surrogate endpoint. The modest clinical effect in the prevention of cognitive decline, despite the effective removal of amyloid plaques, confirms that many other factors are involved in the mechanism. This will need to be considered in further efforts to prevent neurodegeneration and develop disease modifying treatment"},{"@xml:lang":"sl","#text":"Amiloidna hipoteza temelji na predpostavki, da je glavni vzrok Alzheimerjeve bolezni nalaganje zunajceličnih plakov amiloida beta v možganskem tkivu, čemur sledi naknadno pojavljanje znotrajceličnih depozitov proteina tau. Pri razvoju bioloških učinkovin za zdravljenje Alzheimerjeve bolezni so se raziskovalci usmerili predvsem na tarče, povezane z nastankom plakov amiloida beta, nevrofibrilarnih pentelj in na tarče, povezane z aktivnostjo celic nevroglije ter vnetnim odzivom v centralnem živčevju. Največ uspeha so do sedaj dosegla monoklonska protitelesa, usmerjena proti komponentam amiloidne poti. Tako sta pred kratkim po postopku pospešene odobritve zdravila na podlagi doseganja nadomestnega končnega izida dovoljenje za promet v ZDA pridobila adukanumab in lekanemab. Skromen klinični učinek pri preprečevanju kognitivnega upada navkljub učinkovitemu odstranjevanju plakov amiloida beta, potrjuje da so v mehanizem vpleteni še številni drugi dejavniki, kar bo potrebno upoštevati pri nadaljnjem razvoju zdravljenja, ki bo lahko ustavilo nevrodegeneracijo in spremenilo potek bolezni"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-WM3ZV7M3","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-WM3ZV7M3"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-WM3ZV7M3/444e3dc8-14fd-4937-87e8-1195f92ad504/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-WM3ZV7M3/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-WM3ZV7M3"}}}}